Related Experiment Video

Updated: Jul 10, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment

Ying Zhang1, Haili Qian, Chen Lin

  • 1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, No.1 Shuaifuyuan, Dong Dan District, Beijing 100007, PR China.

Gynecologic Oncology
|November 3, 2007
PubMed
Abstract

Insights

Adenovirus-delivered Tissue Inhibitor of Metalloproteinases-3 (Ad-TIMP-3) shows therapeutic potential for cervical cancer. It effectively inhibits tumor growth in vitro and in vivo, with enhanced effects when combined with cisplatin.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Matrix metalloproteinases (MMPs) play critical roles in cervical cancer progression.
  • Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) inhibits MMPs and can retard tumor growth.
  • TIMP-3's bystander effect is advantageous for treating invasive cervical cancer.

Purpose of the Study:

  • To explore the therapeutic applicability of TIMP-3 in human cervical cancer.
  • To evaluate the efficacy of an adenoviral vector carrying TIMP-3 (Ad-TIMP-3).

Main Methods:

  • Constructed a replication-deficient adenoviral vector carrying TIMP-3 (Ad-TIMP-3).
  • Tested Ad-TIMP-3 in cervical cancer cell lines in vitro.
  • Injected Ad-TIMP-3 into tumor xenografts in nude mice in vivo.

Main Results:

  • Ad-TIMP-3 arrested cervical cancer cells in G2/M phase and inhibited growth via bystander effects.
  • Ad-TIMP-3 demonstrated a more potent cell-killing effect than Ad-p53.
  • Combination therapy with Ad-TIMP-3 and cisplatin (cDDP) showed synergistic effects in vitro and significantly inhibited tumor xenografts in vivo.

Conclusions:

  • Ad-TIMP-3 exhibits therapeutic potential for cervical cancer.
  • Gene therapy with Ad-TIMP-3 offers a promising strategy for cervical cancer treatment.
  • Combination of Ad-TIMP-3 with chemotherapy warrants further investigation.

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...